Adam Walsh
Stock Analyst at Roth Capital
(2.66)
# 1,942
Out of 5,149 analysts
14
Total ratings
66.67%
Success rate
15.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Initiates: Buy | $212 | $147.00 | +44.22% | 1 | Jan 23, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $58 | $34.67 | +67.29% | 1 | Jan 23, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $171 | $239.22 | -28.52% | 3 | Apr 20, 2020 | |
| GLPG Galapagos NV | Maintains: Buy | $121 → $188 | $33.05 | +468.84% | 4 | Jul 15, 2019 | |
| CORT Corcept Therapeutics | Downgrades: Hold | n/a | $35.28 | - | 4 | May 31, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $74 → $77 | $22.07 | +248.89% | 1 | Apr 18, 2018 |
Insmed
Jan 23, 2026
Initiates: Buy
Price Target: $212
Current: $147.00
Upside: +44.22%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $34.67
Upside: +67.29%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146 → $171
Current: $239.22
Upside: -28.52%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121 → $188
Current: $33.05
Upside: +468.84%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $35.28
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74 → $77
Current: $22.07
Upside: +248.89%